Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00791440 · ClinicalTrials.gov registry record · NA

Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy

A NA study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
NA
Development phase
34
Enrollment target

NCT00791440: Completed NA study, sponsored by New York State Psychiatric Institute.

NCT00791440 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00791440, a NA study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target

Study Summary

This study examines the impact of Cognitive-Behavior Therapy (CBT) on symptoms, physiological arousal, stressors, and the ways to deal with them in individuals with schizophrenia and related disorders. The primary aim of this study is to investigate the role cognitive coping strategies play in mediating the link between stress, physiological arousal, and psychotic symptoms in individuals with schizophrenia during recovery from psychosis.

Interventions

  • BEHAVIORAL Cognitive-Behavior Therapy
  • OTHER Standard Psychiatric Treatment

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2008-11
Est. Completion 2012-06
Phase NA

What the finished NCT00791440 record still lists

NCT00791440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Cognitive-Behavior Therapy is the first listed.

NCT00791440 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00791440 about?

NCT00791440 is a clinical study titled "Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy". This study examines the impact of Cognitive-Behavior Therapy (CBT) on symptoms, physiological arousal, stressors, and the ways to deal with them in individuals with schizophrenia and related disorders. The primary aim of this study is to investigate the role cognitive coping strategies play in media...

What is the current status of trial NCT00791440?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2008-11. Estimated completion is 2012-06.

What interventions are being tested in trial NCT00791440?

The interventions under investigation include: Cognitive-Behavior Therapy (BEHAVIORAL), Standard Psychiatric Treatment (OTHER).

Who is sponsoring clinical trial NCT00791440?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00791440's enrollment target sits among peer trials

34 1570th of 2000 higher than 427 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00791440, the US trial registry maintained by the National Library of Medicine. NCT00791440 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.